Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
"Too big to fail" is how we would describe the megacap stocks in this article today.
While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their ability to find new sources of growth.
Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025.
FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are working on legislation to ban lawmakers and cabinet members from buying and selling stocks.
Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.
The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.
Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable strength of its diabetes and obesity care segments. The company's flagship weight-loss drug, Wegovy, and the diabetes treatment Ozempic continued their meteoric
